3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Interventions
Imatinib Mesylate
10
Cyclophosphamide
9
fludarabine
8
nilotinib
7
fludarabine phosphate
7
Dasatinib
6
Busulfan
6
Whole-Body Irradiation
5
Tacrolimus
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Melphalan
5
Cytarabine
5
Stem Cell Transplantation
4
Filgrastim
4
Alemtuzumab
4
Cyclosporine
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
thymoglobulin
2
ruxolitinib
2
ponatinib
2
plerixafor
2
bosutinib
2
Thiotepa
2
Sirolimus
2
Granulocyte Colony-Stimulating Factor
2
Everolimus
2
venetoclax
1
vatalanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled